<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632474</url>
  </required_header>
  <id_info>
    <org_study_id>FSCII-ART-1</org_study_id>
    <nct_id>NCT02632474</nct_id>
  </id_info>
  <brief_title>ART Drug Dosage Adjustment in HIV-infected Population</brief_title>
  <official_title>ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of the combination of low dose of&#xD;
      Tenofovir, Efavirenz and Lamivudine in treating HIV-infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The feedback system control (FSC) technique has been developed to rapidly identify optimal&#xD;
      combinations for therapeutic purposes. Low dose of TDF+3TC+EFV combination has been test in&#xD;
      vitro study by FSC which showed high efficacy and now the investigators apply it to human to&#xD;
      further optimize the ART combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4 Count</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Drug Plasma Concentration</measure>
    <time_frame>Day 7,14,21,28</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Low-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)</intervention_name>
    <description>The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).</description>
    <arm_group_label>Low-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV antibody positive&#xD;
&#xD;
          -  HIV RNA below 10*E5 copies/ml&#xD;
&#xD;
          -  CD4 T cell count above 200 cells/ml&#xD;
&#xD;
          -  Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV genotyping resistant to investigating drug&#xD;
&#xD;
          -  Pregnant, breastfeeding, or lactating&#xD;
&#xD;
          -  Any serious or active medical or psychiatric illness which, in the opinion of the&#xD;
             Investigator, would interfere with treatment, assessment, compliance with the&#xD;
             protocol, or subject safety. This would include any active clinically significant&#xD;
             renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal disease)&#xD;
             illness, or malignancy&#xD;
&#xD;
          -  Medical or psychiatric condition or occupational responsibilities that may preclude&#xD;
             compliance with the protocol&#xD;
&#xD;
          -  Laboratory blood values:&#xD;
&#xD;
          -  Haemoglobin &lt;7.0 grams/decilitre (g/dL)&#xD;
&#xD;
          -  Neutrophil count &lt;500/mm3&#xD;
&#xD;
          -  Platelet count &lt;50,000/mm3&#xD;
&#xD;
          -  Aspartate aminotransferase or Alanine transaminase &gt;5 times Upper Limit of Normal&#xD;
             (ULN)&#xD;
&#xD;
          -  Subjects with an estimated creatinine clearance of &lt;50 mL/minute&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>HIV Infections</keyword>
  <keyword>Tenofovir</keyword>
  <keyword>Efavirenz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

